General Information
Hanmi DM2 203
A Phase II, 12-week, double-blind, randomized, parallel group, multi-centre, international trial to assess the effect on glycaemic control of five doses of HM11260C versus placebo or open-label liraglutide in subjects with type 2 diabetes.
| Protocol | HM-EXC-203 |
|---|---|
| Identifier | HM-EXC-203 Site Number 1807 |
| UID | c7b06b7a-2b6a-458d-929c-c850a3bcaac5 |
| Status | Done - Archived |
| Phase | 2 |
| Category | Diabetes Type 2 |
| Launch Year | 2013 |
| NCT Number | - |
| Created | 2013-09-10 18:53 |
| Last Updated | 2013-09-10 18:53 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2013-12-16 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2015-03-04 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Martinez, Gilbert | GJMartinez | No |
| Recruiter | - | No | |
| Coordinator | Pereira, Cynthia | CPereira | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Hanmi Pharmaceuticals Co. Ltd |
|---|---|
| Division | Hanmi Pharmaceuticals Co. Ltd |
| Team | Hanmi Pharmaceuticals Co. Ltd |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | PRA (NC) |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
